Similar articles

• Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.

  Klein RM, Klein RB. Klein RM, et al. Retina. 2007 Nov-Dec;27(9):1163-5. doi: 10.1097/IAE.0b013e31815e9322. Retina. 2007. PMID: 18046218 No abstract available.
• Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.

  Schmucker C, Antes G, Lelgemann M. Schmucker C, et al. Surv Ophthalmol. 2009 Nov-Dec;54(6):705-7. doi: 10.1016/j.survophthal.2009.08.002. Surv Ophthalmol. 2009. PMID: 19818262 Review. No abstract available.
• Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration.

  Kimmelman J. Kimmelman J. Retina. 2007 Nov-Dec;27(9):1166-7. doi: 10.1097/IAE.0b013e31815ee57e. Retina. 2007. PMID: 18046219 No abstract available.
• Intravitreal avastin: the low cost alternative to lucentis?

  Rosenfeld PJ. Rosenfeld PJ. Am J Ophthalmol. 2006 Jul;142(1):141-3. doi: 10.1016/j.ajo.2006.03.036. Am J Ophthalmol. 2006. PMID: 16815262 No abstract available.
• Avastin and new treatments for AMD: where are we?

  Freeman WR, Falkenstein I. Freeman WR, et al. Retina. 2006 Oct;26(8):853-8. doi: 10.1097/01.iae.0000244722.35073.7c. Retina. 2006. PMID: 17031283 Review. No abstract available.